Stroke
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Subjects will be eligible if they have a clinical diagnosis of first or recurrent chronic stroke (>6 months); are > 18 years of age; are inactive or insufficiently active based on the standards of the Centers for Disease Control and Prevention adjusted activity scores on Human Activity Profile (HAP) under 74 (inactive or moderately active) and have medical permission.
Exclusion criteria
Exclusion criteria: Exclusion criteria will be cognitive impairments; as determined by the Mini-Mental State Exam cut-off scores; language impairments (comprehensive aphasia) and pain and/ or other adverse health conditions that might affect their performance in the intervention. Patients who use drugs or who have inflammatory or autoimmune diseases that may interfere with the concentrations of inflammatory mediators or neurotrophins will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: Change in serum concentration in the concentration of inflammatory mediators (IL-6, TNF, sTNFR1, sTNFR2 and IL-10), asssesed by enzyme-liked immunosorbent assay (ELISA), before and after 12 weeks intervention.;Expected outcome 2: Increase in serum concentration of brain derived neurotrophic factor (BDNF), assessed by enzyme-liked immunosorbent assay (ELISA), before and after 12 weeks intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 1: Increase in the mean walk speed in the 10-meter test, before and after 12 weeks intervention. It is expected to increase in gait speed.;Expected outcome 2: Decrease in the reaction time in the Timed Up and Go (TUG) test, before and after 12 weeks intervention. It is expected to decrease in time to perform the test.;Expected outcome 3: Increase in the mean exercise capacity assessed by six minute walk test (6MWT) before and after 12 weeks intervention. The distance traveled is expected to increase. ;Expected outcome 4: Change in immunophenotyping profile (evaluation of receptor expression and cell types of the immune system) by means of the flow cytometry technique. Immunophenotyping will be performed before and after training. | — |
Countries
Brazil
Contacts
Universidade Federal de Minas Gerais